Chemoradiation-Induced Nausea and Emesis: Quality of Life
NCT ID: NCT00394602
Last Updated: 2020-01-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
207 participants
OBSERVATIONAL
2004-04-07
2019-05-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. To assess the preferences of cancer patients scheduled to receive chemoradiation and caregiver controls for side-effects of chemoradiation.
1. To compare preferences of cancer patients to those of healthy individuals.
2. To compare how patients' preferences for side-effects of chemoradiation change over time.
2. To longitudinally assess the quality of life of cancer patients scheduled to receive chemoradiation.
3. To determine the impact of nausea and vomiting associated with chemoradiation on patients' quality of life and evaluate potential change throughout the duration of chemoradiation treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Incidence and Patterns of Nausea/Vomiting With Combined Chemotherapy and Radiation
NCT00716157
Nausea or Vomiting in Patients Who Are Receiving Chemotherapy for Breast Cancer or Lung Cancer
NCT00416689
Prevalence of Anticipatory Nausea and Vomiting in Cancer Patients Exposed to Highly Emetogenic Chemotherapy
NCT04785495
Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea
NCT04937309
Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041)
NCT00211601
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Chemoradiation is a type of cancer treatment that involves both chemotherapy and radiation therapy.
You will also receive a packet of 3 questionnaires to complete at different times during and after treatment. The questionnaires include a quality of life survey that asks about physical, social, and emotional well-being, a self-report symptom evaluation that will ask whether you are experiencing any particular side effects and if so how much it bothers you, and a brief survey to asks questions about anxiety and distress.
The questionnaires should take about 20 minutes each to complete. The questionnaire packet will be given to patients at the beginning of chemoradiation treatment, 3 weeks after treatment starts, the last day of treatment, and at the first follow-up appointment after chemoradiation treatment ends. If the you do not have time to complete the questionnaires, a stamped, addressed envelop will be given so that you can mail the completed packet back to the research team.
Your participation in this research study will be over about 4-6 weeks after chemoradiation treatment ends.
This is an investigational study. Up to 208 individuals (104 patients and 104 caregivers) will take part in this study. All will be enrolled at M. D. Anderson.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients
Patients receiving chemoradiation for abdominal-pelvic tumors.
Interview
Interview regarding perceptions of side effects that are related to chemoradiation treatment.
Questionnaire
3 Questionnaires regarding quality of life given during and after treatment, each taking about 20 minutes to complete.
Caregiver Controls
Healthy controls with no prior cancer diagnosis.
Interview
Interview regarding perceptions of side effects that are related to chemoradiation treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Interview
Interview regarding perceptions of side effects that are related to chemoradiation treatment.
Questionnaire
3 Questionnaires regarding quality of life given during and after treatment, each taking about 20 minutes to complete.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients receiving concurrent abdominal-pelvic radiation and single agent or combination of cisplatin, paclitaxel, CPT-11, oxaliplatin or 5-FU, capecitabine, gemcitabine, or bevacizumab (Avastin).
3. Patients must be least 18 years of age
4. Controls must be individuals with no prior cancer diagnosis
5. Controls must be at least 18 years of age
6. Controls must be the caregivers of patients on this study
Exclusion Criteria
2. Patients who are not scheduled to receive chemoradiation treatment
3. Patients who are not at least 18 years of age
4. Controls - individuals who have a prior diagnosis of cancer (with the exception of non-melanoma skin cancer)
5. Controls - individuals who are not at least 18 years of age
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Charlotte C. Sun, MD
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
University of Texas MD Anderson Cancer Center Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2003-0529
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.